We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

8 hedge funds and large institutions have $3.42M invested in Trillium Therapeutics Inc. in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
8
Holders Change
+8
Holders Change %
–
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$2.6M
2
TDC
Thompson Davis & Co
Virginia
+$39.1K
3
TRCT
Tower Research Capital (TRC)
New York
+$12.8K
4
FMA
FNY Managed Accounts
New York
+$11.7K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$305

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$3M +$2.6M +333,333 New
KPF
2
K2 Principal Fund
Ontario, Canada
$178K +$155K +19,783 New
ACP
3
Acuta Capital Partners
California
$171K +$148K +19,000 New
TDC
4
Thompson Davis & Co
Virginia
$45K +$39.1K +5,000 New
TRCT
5
Tower Research Capital (TRC)
New York
$15K +$12.8K +1,632 New
FMA
6
FNY Managed Accounts
New York
$13.5K +$11.7K +1,500 New
Toronto Dominion Bank
7
Toronto Dominion Bank
Ontario, Canada
– +$47 +6 New
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
– +$305 +39 New

TRIL Hedge Fund Activity: Q4 2014 in Review

8 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2014, worth a combined $3.42M.

Buyers outnumbered sellers: 8 funds opened new TRIL positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $2.6M.

  • 8 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2014, up from 0 in Q3 2014.
  • Funds reported $3.42M of Trillium Therapeutics Inc. stock for Q4 2014.
  • 8 funds opened new Trillium Therapeutics Inc. positions in Q4 2014 and 0 closed out, a net change of +8 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q4 2014 was Opaleye Management, an estimated $2.6M added.

Based on aggregated 13F filings for Q4 2014.